Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]

read more

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

Interim results from an ongoing clinical trial of lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma (RCC) who have already received an immune checkpoint inhibitor. The trial included up to 360 patients with various cancers, of which 33 patients had metastatic clear cell RCC. The patients took a […]

read more

Current role of mTOR inhibitors in metastatic kidney cancer

The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here

read more

Advances in kidney cancer drug treatments shake up drug choices

The following article provides a comprehensive summary of the changing landscape in the choice of first and second-line drug treatments for advanced kidney cancer, with input from Dr Eric Jonasch, a professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center and vice chair of the Kidney Cancer Guidelines Committee for […]

read more

Combination therapy is promising for kidney cancer

In recent years, drugs that target the vascular endothelial growth factor (VEGF) pathway, such as Sutent (sunitinib), Votrient (pazopanib), Nexavar (sorafenib), Inlyta (axitinib) and Avastin (bevacizumab), have been successful at improving the life expectancy of patients with metastatic renal cell carcinoma (RCC). However, for many patients anti-VEGF therapy fails and their disease eventually progresses. Immunotherapies, […]

read more

Eisai has started phase III clinical trial with lenvatinib as a potential first-line treatment for advanced kidney cancer

This week saw the initiation of a global phase III clinical trial of lenvatinib, a multiple receptor tyrosine kinase inhibitor, in combination with everolimus and the anti-PD-1 antibody, pembrolizumab, as a potential first-line treatment for advanced renal cell carcinoma (RCC). The trial is called the CLEAR study, and is being run by the Japanese pharmaceutical company, Eisai. […]

read more

European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer

The European Commission has approved Kisplyx (lenvatinib) for the treatment of people with advanced renal cell carcinoma (RCC). Lenvatinib is a new, more potent tyrosine kinase inhibitor, that is given in combination with everolimus for the treatment of people with advanced RCC following the failure of one prior vascular endothelial growth factor (VEGF) targeted therapy. Lenvatinib […]

read more

Cabozantinib and lenvatinib recommended for approval by the EMA

Cabozantinib (Cabometyx, Ipsen Pharma) and lenvatinib (Kisplyx, Eisai Europe Ltd) have been recommended for approval by the European Medicines Agency (EMA). This will soon give kidney cancer patients in Europe, who are not responding to treatment, two new options to try. The EMA is the European Union agency responsible for the protection of public and animal […]

read more

Lenvatinib plus everolimus improves progression-free survival in renal cell carcinoma

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week show that lenvatinib (Lenvima) plus everolimus (Afinitor) in kidney cancer significantly improved progression free survival (PFS) compared with everolimus or lenvatinib alone. Patients with metastatic renal cell carcinoma (mRCC) treated with lenvatinib plus everolimus following one prior VEGF targeted therapy […]

read more
Showing 1 to 10 of 11 results
  TOP